Tesla Model 3 Tesla's Stock Price

Previewing The Week: Apple, Exact Sciences, Tesla – Plus New Model 3 Pics.


Big Earnings Week Ahead

What a week it will be for earnings, with Apple ($AAPL), Facebook ($FB), and Tesla ($TSLA) being three of the most prominent names to come. While exciting companies like Exact Sciences ($EXAS), Mastercard ($MA), Under Armour ($UAA), Qualcomm ($QCOM), Alibaba ($BABA), and Starbucks ($SBUX). Below is a calendar with the dates and expectations.

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row] Subscribe

 

EARNINGS WEEK OF 10.31.17

[poll id=”8″]



 

Exact Sciences

EXAS Chart

EXAS data by YCharts

Exact Sciences is not a name most investors are familiar with but should get to know. Its stock is up nearly 285 percent in 2017, yes you read that right. The S&P 500, by comparison, is up only 15.25 percent. The meteoric rise in Exact Science has been fueled by its lead product Cologuard, a noninvasive test for the detection of Colon Cancer. Wall Street is looking for the company to show revenue grew by 131 percent since last year to $65.03 million while looking a net loss of $0.30. The company boast a $6 billion valuation and is expected to see revenue grow to $566 million by the year 2019. The company has been able to easily beat revenue estimates for each of the last two quarters.

EXAS Quarterly Actual Revenue Chart

EXAS Quarterly Actual Revenue data by YChartsa

[poll id=”9″]

Apple

Apple is the most critical company to report this week, and everyone will be watching to see not only what results are, but more importantly the guidance for next quarter, the year, and the launch of the new iPhone’s. Expectations are for revenue of $50.76 billion, and EPS of $1.87, while for the fiscal first quarter analysts are looking for revenue of $85.73 billion on EPS of $3.79. So regardless of how Apple reports this past quarter results, the market will likely only care about guidance for the fiscal first quarter, and of course iPhone shipments and demand. It is an outcome that will ripple throughout the iPhone supply chain.

Premium Content:

What Good Are The Analyst Worth!

Dollar Breakout, Bad For Euro

GE And Celgene, Plus FAANG’s

Tech, Biotech, And Why BofA Can Go To $40

Biotech Could Falter

Tesla

Tesla reports this week as well, with expectations for revenue of $2.92 billion, and a net loss of $2.27. It will be all about Capex and cash burn, and of course the Model 3 launch. Any color around the “production hell” and perhaps more critical any updates to that 5,000 cars per week by December target. I can tell you I saw a Model 3 just yesterday at the Americana Mall in Manhasset. It is a very sleek looking car, although it is much smaller than I had imagined., which is perhaps why Tesla can get so much range on the car, despite the battery size. Additionally, it was discretely parked between two Model X SUV’s. It had no marking of the Model 3 on the trunk, which I found interesting.

Model 3 Pictures – Tesla Store Americana Mall, Long Island NY

Model 3

Model 3 Back

 

 

 

 

 

 

 

 

 

Whatever the case it sure was cool to see the real thing.

The other companies will be sure essential to watch as well. Hope this helps get your week going.

Free Articles From Mike:

Celgene and Biogen May Be Signalling A Biotech Bottom

AMD Could Rise 10% Despite Results, Trades Indicate

Why Tesla’s Stock Is Breaking Down

Why Is McDonald’s Valued Like a Big Tech Stock?

Why Biogen May Sink Biotech Sector As Earnings Beat

Netflix Stock Likely to Rise as EPS Estimates Jump

Bank of America Could Rise Nearly 50%: Technical Analysis

AMD Could Break Out After Results

Qualcomm’s Bid For NXP Still Lacks Investor Support

Celgene’s Sharp Sell-Off Is Likely Overdone

Procter & Gamble Continues To Have Two Big Problems

GE: Getting Excited For The Future

Why IBM’s Big Stock Rally Won’t Last

Allergan Shares On The Verge Of Further Breakdown

We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get this all and of all free commentaries sent directly to your inbox or follow us on Twitter.

-OR-

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]

clients of Mott Capital own shares of TSLA, MA, SBUX

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

 

 

Comments are closed.